A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Rizatriptan 10 mg Oral Disintegrating Tablet for Treatment of Acute Attacks of Chronic, Blast-induced, Post-traumatic Headache in U.S. Military Troops.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Rizatriptan 10 mg Oral Disintegrating Tablet for Treatment of Acute Attacks of Chronic, Blast-induced, Post-traumatic Headache in U.S. Military Troops.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2015

At a glance

  • Drugs Rizatriptan (Primary)
  • Indications Post-traumatic headache
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 09 Nov 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top